Clinical Trial
Phase II Study of Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Learn more about this study at
clinicaltrials.gov
For more information contact us here:
Phone
800-600-3606Brief Summary
Advanced pancreatic cancer patients receiving treatment of adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant defactinib plus avutometinib will have increased progression-free survival (PFS) compared to historical PFS rates for patients receiving adaptive SBRT alone.
Protocol Interventions
Radiation: Stereotactic body radiotherapy
Learn About Clinical Trials
Clinical trials are research studies that help us find new ways to prevent, diagnose, and treat cancer. If you are interested in participating in a clinical trial, our team will help you find a study that is right for you. Call us to speak with a Siteman care coordinator.